Kibur Hunie Tesfa

Dr. Kibur Hunie Tesfa


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in Metabolism Open
Verified
Journal Article
Open access
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
CGChernet Desalegn Gebeyehu
Chernet Desalegn Gebeyehu
AEAsrat Tadele Ewunetie
Asrat Tadele Ewunetie
EGEndalkachew Gugsa
Endalkachew Gugsa
ANAmare Nigatu Nigatu
Amare Nigatu Nigatu
HEHiwot Tezera Endale
Hiwot Tezera Endale
Type 2 diabetes mellitus (T2DM) is the most common group of metabolic disorders in the world, characterized by hyperglycemia that leads to severe short-term complications such as ketoacidosis, hyperosmolar hyperglycemic coma, and long-term microvascular complications that affect the eye, kidney, and nerves. Type 2 diabetes occurs due to resistance to insulin. AMPK (adenosine monophosphate-activated protein kinase) is an energy radar that controls various metabolic and physiological processes. It is dysregulated in major chronic diseases, such as diabetes. The focus of this review is on understanding the role of AMPK in type 2 diabetes mellitus, which helps ameliorate hyperglycemia and its complications. Medications for T2DM are designed to upregulate the AMPK signaling pathway to improve its microvascular and macrovascular complications. AMPK signaling interacts with PGC-1, PI3K/Akt, NOX4, NF-κB, and other molecular pathways to produce such protective effects. Thus, AMPK is emerging as one of the most auspicious targets for both the prevention and treatment of type 2 diabetes mellitus. Hence, this review focuses on the recent evidence of the role of AMPK signaling in type 2 diabetes mellitus pathogenesis and how to circumvent its complications.

26 August 2024 in Metabolism Open
Verified
Journal Article
Open access
ODOman Philmon Daka
Oman Philmon Daka
TJTesfahun Bekele Jember
Tesfahun Bekele Jember
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
Background: Hypertension is a major public health problem in developing countries. Globally, nearly 1.13 billion adults had hypertension in 2015 and this is estimated to increase to 1.56 billion by 2025. Hyperuricemia is an important predictor of the progression of hypertension and is common in hypertensive patients. Hypertensive patients with hyperuricemia are at higher risk of cardiovascular disease. Objective: To assess the prevalence of hyperuricemia and its associated factors among hypertensive patients attending the University of Gondar Comprehensive Specialized Hospital (UGCSH). Method: An institutional-based cross-sectional study was conducted on 248 hypertensive patients attending the University of Gondar Comprehensive Specialized Hospital from January 2020 to February 2021. A convenient sampling technique was employed to select study participants. Socio-demographic and clinical characteristics were collected using a structured questionnaire via face-to-face interviews and reviewing medical records respectively. The biochemical parameters were measured by using a Mindray BS-200E chemistry analyzer. Data was entered using EpiData version 4.6.0.0 and analyzed using STATA vs. 14.0. Bivariable and multivariable binary logistic regression were fitted to identify factors associated with hyperuricemia. The odds ratio and 95 % CI were calculated to assess the strength of the association and a P-value <0.05 in the multivariable was considered statistically significant. Results: A total of 248 patients were enrolled; 140 (56.5 %) were female. The mean age of patients was 57.9 ± 10.5 years. The overall prevalence of hyperuricemia was 42.3 %; males had a prevalence of 36.1 % and females of 47.1 %. High waist circumference, high body mass index, dyslipidemia, low estimated Glomerular Filtration Rate, elevated fasting blood glucose, elevated total cholesterol, elevated triglycerides, elevated Low-Density Lipoprotein cholesterol, and Low High-Density Lipoprotein cholesterol were found to be significantly associated with hyperuricemia. Conclusion: This study demonstrated the predominant existence of hyperuricemia in hypertensive patients. Therefore, early diagnosis and monitoring of hyperuricemia are required before further complications occur.

20 April 2026 in Metabolism Open
Verified
Journal Article
Open access
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
AZAmare Nigatu Zewdie
Amare Nigatu Zewdie
Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities including abdominal obesity, impaired glucose metabolism, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and hypertension. It is diagnosed when at least three of these five criteria are present. Individuals with MetS are at increased risk of developing type 2 diabetes mellitus and cardiovascular disease. Beyond these well-established complications, infertility has emerged as an underrecognized consequence of metabolic dysfunction. Infertility, defined as failure to achieve pregnancy after one year of regular unprotected intercourse, affects approximately 10–15% of couples worldwide, with nearly 20% of cases classified as idiopathic. This review aims to examine the impact of metabolic syndrome and its components on male and female infertility and to highlight the potential mechanisms linking metabolic disturbances with impaired reproductive function. A narrative review of current literature was conducted, focusing on the relationship between metabolic syndrome components - obesity, dyslipidemia, hyperinsulinemia, and hypertension - and reproductive health outcomes. Evidence from clinical, epidemiological, and experimental studies evaluating reproductive dysfunction in both males and females was analyzed. Metabolic syndrome exerts significant adverse effects on reproductive health in both women and men. In women, it is associated with reduced ovulation, impaired oocyte competence, diminished follicular reserve, anovulation, and increased risk of ovarian pathology. In men, MetS contributes to reduced sperm count, impaired sperm motility and viability, poor semen quality, erectile dysfunction, and prostate-related disorders. Early identification and proper management of metabolic syndrome may play a crucial role in reducing the burden. Addressing metabolic abnormalities through lifestyle modification and appropriate medical interventions could improve reproductive outcomes.

6 January 2025 in Phytomedicine Plus
Verified
Journal Article
Open access
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
CGChernet Desalegn Gebeyehu
Chernet Desalegn Gebeyehu
TMTiget Ayelgn Mengstie
Tiget Ayelgn Mengstie
HEHiwot Tezera Endale
Hiwot Tezera Endale

9 May 2026 in Pharmacological Research - Natural Products
Verified
Journal Article
Closed access
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
CGChernet Desalegn Gebeyehu
Chernet Desalegn Gebeyehu
ASAdamu Ambachew Shibabaw
Adamu Ambachew Shibabaw
ACAlex Ayenew Chereka
Alex Ayenew Chereka
GKGemeda Wakgari Kitil
Gemeda Wakgari Kitil
AEAsrat Tadele Ewunetie
Asrat Tadele Ewunetie

21 July 2026 in American Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
KTKibur Hunie Tesfa
Kibur Hunie Tesfa
AZAmare Zewdie
Amare Zewdie
GDGashaw Dessie
Gashaw Dessie
YYYadelew Yimer
Yadelew Yimer
HAHassen Ahmed
Hassen Ahmed
MKMulugeta Kassaw
Mulugeta Kassaw
Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. Many plant species have been screened for their pharmacological properties in the treatment of diabetes mellitus. Cordia africana is a traditional medicinal plant used to treat various health problems. The objective of this study is to evaluate the effect of hydromethanolic leaf extract of Cordia africana (Wanza) on blood glucose levels, serum electrolytes, and α-amylase inhibitory activities in Streptozotocin-induced diabetic mice. The method used is an experimental study conducted on streptozotocin-induced diabetic male mice. The mice were organized into 6 groups, each having five members: normal mice (negative control), diabetics treated with distilled water (positive control), diabetics treated with glibenclamide (standard control), and the other three groups were diabetic mice treated with different doses of leaf extract. Their fasting blood sugar was measured on the 0 th , 7 th , and 14 th days of the experiment. Serum electrolytes (Na + , K + , Cl − , and Ca 2+ ) had also been determined on the 14 th day of the experiment. The antioxidant properties and in vitro α-Amylase inhibitory actions of the extract had also been evaluated. The acute toxicity profile of the extract was assessed in 5 randomly selected female mice. The results of the study revealed that the hydromethanolic leaf extract of Cordia africana has a significant blood glucose-lowering effect. On the 7 th and 14 th day, the mean blood glucose levels of diabetic mice treated with 5mg glibenclamide, 200 mg/kg, and 400 mg/kg extract significantly diminished. Deranged serum electrolytes (Na + , K + , Cl − , and Ca 2+ ) and reduced body weight were significantly improved at both doses of the extract, as well as in 5mg glibenclamide-treated mice. Besides, good antioxidant and α-amylase inhibitory activity were obtained from the in vitro lab tests. In conclusion, the results of this study exhibited that the hydromethanolic leaf extract of Cordia africana remarkably reduces blood sugar and body weight in streptozotocin-induced diabetic mice. Likewise, it improves deranged serum electrolytes. The extract also inhibits α-amylase activities.